Today, a growing number of people, including children and young adults, are being subjected to various kinds of cancers, adding urgency to the search for treatments that are effective and tolerable. Families facing aggressive cancers often find themselves navigating therapies that can be physically demanding, particularly when standard treatments are rendered futile. Against that backdrop, Aminex Therapeutics has spent more than a decade pursuing a scientific pathway that remains elusive in the broader medicine world.
According to Jeff Judson, the company's Vice President, Aminex is currently conducting a clinical trial specifically targeting polyamine metabolism in cancer. Polyamines are naturally occurring compounds that tumor cells rely on to multiply rapidly and evade the immune system. The company's investigational approach combines its proprietary drug, AMXT 1501, with difluoromethylornithine (DFMO), a drug that recently gained FDA approval under the name Iwilfin for reducing relapse risk in children with neuroblastoma.
